NEW YORK — Neogen said on Wednesday that its genomics business has received a Clinical Laboratory Improvement Amendments (CLIA) certificate of compliance from the Centers for Medicare & Medicaid Services.
With the CLIA certification, the Lincoln, Nebraska-based business — called Neogen Genomics — may conduct human genotyping, allowing it to perform a range of clinical research projects and high-throughput genetic variant screening, as well as participate in the interrogation of methylation patterns at the genome-wide level for epigenome-wide association studies.
"By earning this CLIA certification, we are able to expand our genomics services into the field of human testing, offering our world-leading services to a variety of new institutions, be involved in new forms of screening, and contribute to research into the human genome," Neogen President and CEO John Adent said in a statement.
Neogen currently offers a range of products and testing services for food and animal safety including DNA sequencing for livestock, diagnostic testing for allergen detection, and sanitation monitoring systems.
In December, the Lansing, Michigan-based company acquired companion animal genetic testing firm Paw Print Genetics. That same month, it signed an agreement to merge its existing operations with 3M's food safety business.